Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by George, R. B.
Right arrow Articles by Kinasewitz, G. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by George, R. B.
Right arrow Articles by Kinasewitz, G. T.

Chest, Vol 83, 457-460, Copyright © 1983 by American College of Chest Physicians

ARTICLES

Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease

RB George, K Manocha, JG Burford, SA Conrad and GT Kinasewitz

Labetalol is a new adrenergic antagonist with both alpha- and beta- blocking effects. To evaluate its usefulness in the treatment of hypertension in patients with coexisting chronic obstructive pulmonary disease (COPD), labetalol was administered in gradually increasing doses to a group of 11 patients with mild-to-moderate hypertension and COPD with a mild reversible component. Ten patients given hydrochlorothiazide served as control subjects. Blood pressure was controlled in seven of the 11 patients given labetalol and in six of the ten patients given hydrochlorothiazide in dosages up to 1,200 mg/day and 150 mg/day, respectively. No significant changes occurred in the FEV1 or FEF25-75% two hours after the administration of the maximum dose of either drug or after exercise on the same day. Labetalol was well tolerated in the doses given.


This article has been cited by other articles:


Home page
 HeartHome page
R J Shelton, A S Rigby, J G F Cleland, and A L Clark
Effect of a community heart failure clinic on uptake of {beta} blockers by patients with obstructive airways disease and heart failure
Heart, March 1, 2006; 92(3): 331 - 336.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
M. Egred, S. Shaw, B. Mohammad, P. Waitt, and E. Rodrigues
Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease
QJM, July 1, 2005; 98(7): 493 - 497.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter
Cardioselective {beta}-Blockers in Patients with Reactive Airway Disease: A Meta-Analysis
Ann Intern Med, November 5, 2002; 137(9): 715 - 725.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1983 by the American College of Chest Physicians.